ArticleCureus2025
Effective Management of Familial Erythrokeratoderma Using Topical Calcipotriol.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive symmetrical erythrokeratoderma (PSEK) is a rare genodermatosis that is inherited in an autosomal dominant pattern. It is clinically characterized by the insidious onset of well-defined, non-migratory, erythematous, hyperkeratotic plaques in a symmetrical distribution over the extremities. Hereby, we describe two cases of PSEK in a father and daughter, who presented with bilaterally symmetrical hyperpigmented scaly plaques, with skin biopsy findings suggestive of erythrokeratoderma. The skin lesions resolved with topical calcipotriol monotherapy, without the use of topical corticosteroids or oral medications. During telephonic follow-up, the patients reported that recurrences also responded well to topical calcipotriol, without the need for additional medication. This case report highlights the use of topical calcipotriol as a safe and effective therapeutic alternative for the treatment of erythrokeratoderma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.